Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Inflammatory and Genetic Predictors of Cognitive and Emotional Recovery After Critical Illness (CORE-ICU)

16 juni 2026 bijgewerkt door: Sol Fernandez-Gonzalo, Corporacion Parc Tauli

Unraveling the Role of Cognitive Reserve, Inflammatory Phenotype and Genetic Vulnerability on Cognitive and Emotional Recovery After Critical Illness

Survivors of critical illness frequently develop persistent cognitive and emotional impairments, known as post-intensive care syndrome (PICS), which substantially impact quality of life and long-term recovery. While prior research has mainly focused on identifying risk factors, the mechanisms underlying resilience to these sequelae remain poorly understood. Emerging evidence suggests that biological factors, including inflammatory responses and genetic vulnerability, together with cognitive reserve, may play a key role in shaping recovery trajectories.

The aim of this multicenter, prospective observational study is to investigate how cognitive reserve, inflammatory phenotype, and genetic profiles interact to influence cognitive and emotional recovery after critical illness. Adult patients will be recruited at Intensive Care Unit (ICU) admission across two centers in Spain. Clinical and sociodemographic data will be collected during the ICU stay, and biological samples obtained early after admission will undergo transcriptomic and genetic analyses. Cognitive and emotional outcomes will be assessed at hospital discharge and at 3 and 12 months post-discharge using standardised neuropsychological and telemedicine-based evaluations.

By integrating clinical, biological, and cognitive data, this study seeks to identify recovery phenotypes and resilience mechanisms in PICS. The results may contribute to improved risk stratification, inform personalized interventions, and support the development of future strategies aimed at reducing the long-term burden of critical illness.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Studietype

Observationeel

Inschrijving (Geschat)

114

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Critically ill patients admitted to the medical / post-surgical ICU of the Parc Tauli Hospital (Sabadell, Spain), and to the Hospital Universitario Central de Asturias.

Beschrijving

Inclusion Criteria:

  • Adult patients (≥18 years)
  • Admitted to a medical-surgical ICU or cardiac ICU for causes of critical illness (e.g., acute pulmonary oedema, myocardial infarction, aortic dissection)
  • With or without the need for invasive mechanical ventilation
  • With an expected ICU stay of ≥48 hours
  • Resident in Catalonia or the Principality of Asturias
  • Who speak Catalan and/or Spanish
  • Who are able to provide informed consent personally or through an authorised representative (e.g., a family member)

Exclusion Criteria:

  • Non-authorisation by the patient and/or relatives for inclusion in the study
  • Patients admitted to a neurocritical ICU
  • History of severe neurological disease (including dementia or focal brain injury with functional and cognitive impairment) prior to ICU admission
  • History of severe psychiatric disorders (schizophrenia, bipolar disorder, major depressive disorder)
  • Intellectual disability (IQ <80) or other neurodevelopmental disorders, such as autism spectrum disorder
  • Patients who develop secondary complications (e.g., infections, stroke, traumatic brain injury, or other non-transient acquired brain injury) after ICU discharge that may compromise the results of emotional and neuropsychological evaluations during the recovery phase
  • Moderate to severe cognitive impairment (Short-IQCODE >57) preventing independent participation in telemedicine or face-to-face follow-up
  • Readmission to the ICU within 12 months after ICU discharge
  • Language barrier (non-Spanish- and/or non-Catalan-speaking patients)
  • Patients with a life expectancy <1 year or not eligible for active treatment measures

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Critically ill patients (Parc Taulí Hospital)
Critically ill patients (Hospital Universitario Central de Asturias)

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Cognitive Reserve
Tijdsspanne: Within 24-48 hours after ICU discharge

Rami- Cognitive Reserve Questionnaire Score range: 0-25

Cognitive Reserve levels:

Low: 0-6 Medium-low: 7-9 Medium-high: 10-14
Within 24-48 hours after ICU discharge

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Inflammatory phenotypes
Tijdsspanne: Within 24-48 hours of ICU admission
To characterize inflammatory and anti-inflammatory response phenotypes using transcriptomic and biomarker data
Within 24-48 hours of ICU admission
APOE genotype
Tijdsspanne: Within 24-48 hours of ICU admission
To characterize pathological aging mechanisims with APOE genotype
Within 24-48 hours of ICU admission
Level of consciousness
Tijdsspanne: During ICU stay (up to 28 days)
Measured using the Richmond Sedation-Agitation Scale (RASS) Score range: from -5 (unarousable) to +5 (agitated)
During ICU stay (up to 28 days)
Illness severity
Tijdsspanne: During ICU stay (up to 28 days)

Assessed using the Sequential Organ Failure Assessment (SOFA) questionnaire

Score range: 0-24; 0-6: Mild organ dysfunction 7-9: Moderate severity 10-12: Significant organ dysfunction 13+: Severe illness with substantially increased mortality risk
During ICU stay (up to 28 days)
Comorbidity burden
Tijdsspanne: During ICU stay (up to 28 days)

Measured using the Charlson Comorbidity Index (CCI)

0-1 point: Low comorbidity (absence of comorbidities or only very mild diseases).

2-3 points: Moderate to low comorbidity. 4 points or more: Severe comorbidity or high risk.
During ICU stay (up to 28 days)
Frailty level
Tijdsspanne: During ICU stay (up to 28 days)

Assessed using the Rockwood Clinical Frailty Scale (CFS)

Score range from 0 to 9; 1-3: Fit / Non-frail 4: Vulnerable / Very mild frailty 5: Mild frailty 6: Moderate frailty 7-8: Severe to very severe frailty 9: Terminal illness
During ICU stay (up to 28 days)
Presence of delirium
Tijdsspanne: During ICU stay (up to 28 days)
Assessed using the Confusion Assessment Method for the ICU (CAM-ICU) Recorded as Yes/No
During ICU stay (up to 28 days)
Need and type of mechanical ventilation
Tijdsspanne: During ICU stay (up to 28 days)

Categorised as:

  • no mechanical ventilation
  • invasive mechanical ventilation
  • high-flow oxygen therapy
  • non-invasive mechanical ventilation
During ICU stay (up to 28 days)
Sedation treatment
Tijdsspanne: During ICU stay (up to 28 days)

Type of sedative agents administered:

  • none
  • propofol
  • midazolam
  • remifentanil
  • dexmedetomidine
During ICU stay (up to 28 days)
Benzodiazepine use
Tijdsspanne: During ICU stay (up to 28 days)
Recorded as Yes/No
During ICU stay (up to 28 days)
Global cognitive function (MoCA)
Tijdsspanne: At 3 months and 12 months after ICU discharge

Assessed using the Montreal Cognitive Assessment (MoCA) Score range: 0-30

Interpretation:

26-30 Normal cognitive function 18-25 Mild cognitive impairment (possible) 10-17 Moderate cognitive impairment <10 Severe cognitive impairment
At 3 months and 12 months after ICU discharge
Attention and working memory
Tijdsspanne: At 3 months and 12 months after ICU discharge
Assessed using Digit Span Forward and Backward (WAIS-IV); Scaled score range: 1-19. Higher scores indicate better performance; scores <8 suggest impairment.
At 3 months and 12 months after ICU discharge
Verbal memory
Tijdsspanne: At 3 months and 12 months after ICU discharge
Assessed using the Rey Auditory Verbal Learning Test (RAVLT); Total score range recall varies (typically 0-75). Higher scores indicate better verbal learning and memory.
At 3 months and 12 months after ICU discharge
Processing speed
Tijdsspanne: At 3 months and 12 months after ICU discharge
  • Assessed using Coding (WAIS-IV); Scaled score range 1-19. Higher scores indicate better processing speed; scores <8 suggest impairment.
  • Assessed using the Symbol Digit Modalities Test (SDMT); Higher scores indicate better processing speed.
At 3 months and 12 months after ICU discharge
Cognitive flexibility
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Trail Making Test Part B (TMT-B); measured in seconds. Lower completion time indicates better performance.
At 3 and 12 months after ICU discharge
Inhibitory control
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Stroop Colour and Word Test. Higher scores indicate greater impairment in inhibitory control.
At 3 and 12 months after ICU discharge
Verbal fluency
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Phonetic Fluency (FAS) Test; measured as the number of words generated. Higher scores indicate better verbal fluency.
At 3 and 12 months after ICU discharge
Depression
Tijdsspanne: At 3 and 12 months after ICU discharge

Assessed using the Patient Health Questionnaire-9 (PHQ-9).

Score range 0-27;

0-4: None 5-9: Mild 10-14: Moderate 15-19: Moderately severe 20-27: Severe
At 3 and 12 months after ICU discharge
Anxiety
Tijdsspanne: At 3 and 12 months after ICU discharge

Assessed using the Generalized Anxiety Disorder-7 (GAD-7).

Score range 0-21;

0-4: Minimal 5-9: Mild 10-14: Moderate 15-21: Severe
At 3 and 12 months after ICU discharge
Post-traumatic stress disorder
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Treatment-Outcome Posttraumatic Stress Disorder Scale (TOP-8) Score range 0-32. Higher scores indicate greater PTSD symptom severity.
At 3 and 12 months after ICU discharge
Perceived cognitive deficits
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Perceived Deficits Questionnaire (PDQ-D5). Score range 0-20. Higher scores indicate greater perceived cognitive impairment.
At 3 and 12 months after ICU discharge
Fatigue
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the FACIT Fatigue Scale (FACIT-F). Score range 0-52. Lower scores indicate greater fatigue, while higher scores indicate less fatigue.
At 3 and 12 months after ICU discharge
Pain
Tijdsspanne: At 3 and 12 months after ICU discharge

Assessed using the Visual Analogue Scale (VAS-10).

Score range 0-10;

0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe
At 3 and 12 months after ICU discharge
Dyspnea
Tijdsspanne: At 3 and 12 months after ICU discharge

Assessed using the Visual Analogue Scale (VAS-10).

Score range 0-10;

0: No symptoms 1-3: Mild 4-6: Moderate 7-10: Severe
At 3 and 12 months after ICU discharge
Sleep quality
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Pittsburgh Sleep Quality Index (PSQI). Score range 0-21. Scores >5 indicate poor sleep quality.
At 3 and 12 months after ICU discharge
Resilience (post-traumatic growth)
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the Posttraumatic Growth Inventory (PTGI). Score range 0-105. Higher scores indicate greater post-traumatic growth.
At 3 and 12 months after ICU discharge
Quality of life
Tijdsspanne: At 3 and 12 months after ICU discharge
Assessed using the 12-Item Short Form Health Survey (SF-12). Score range 0-100. Higher scores indicate better health-related quality of life.
At 3 and 12 months after ICU discharge

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Corporacion Parc Tauli

Medewerkers

Hospital Universitario Central de Asturias

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 juli 2026

Primaire voltooiing (Geschat)

1 september 2027

Studie voltooiing (Geschat)

1 juni 2028

Studieregistratiedata

Eerst ingediend

28 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 juni 2026

Eerst geplaatst (Werkelijk)

22 juni 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 juni 2026

Laatste update ingediend die voldeed aan QC-criteria

16 juni 2026

Laatst geverifieerd

1 juni 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • PID2024-160948OA-I00

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

The data generated will be deposited in recognized open access repositories, accompanied by clear and standardized metadata, which will facilitate its discovery and reuse by other researchers (Institutional reference repository: CORA https://dataverse.csuc.cat/).

These measures not only ensure responsible treatment of data, but also guarantee their reuse and control

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren